Unknown PHASE3 INTERVENTIONAL NCT00516464

Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Evaluation of Ranibizumab on the Ease of Procedure and Complication Rate in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy

Sponsor: Genentech, Inc.

Conditions Proliferative Diabetic Retinopathy

Interventions Lucentis (ranibizumab)

Updated 5 times since 2017 Last updated: Aug 14, 2007 Started: Aug 31, 2007 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00516464, this PHASE3 trial focuses on Proliferative Diabetic Retinopathy and remains ongoing. Sponsored by Genentech, Inc., it has been updated 5 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Aug 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
Retina Associates, Kansas City

Data source: Retina Associates, Kansas City

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shawnee Mission, United States